AQST · XBRL financial data

Aquestive Therapeutics financial statements, every fiscal year

The same tables from 11 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AQST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	45,849	50,832	47,680	50,583	57,561	44,545
Cost of goods and services sold	12,964	—	19,386	20,831	17,872	18,555
Research and development	19,886	17,047	17,481	13,104	20,280	17,192
Selling, general and administrative	55,892	53,475	52,879	31,750	50,180	79,849
Total operating expenses	88,742	85,511	89,746	—	—	—
Operating income (loss)	(42,893)	(34,679)	(42,066)	(15,102)	(30,771)	(71,051)
Interest income	132	—	—	—	—	—
Interest expense	11,064	10,049	6,552	6,337	11,122	11,120
Income tax expense (benefit)	0	0	0	245	(14)	0
Net income (loss)	(55,783)	(70,539)	(54,410)	(7,870)	(44,137)	(83,784)
Earnings per share, basic USD per share	(1.66)	(1.85)	(1.12)	(0.13)	(0.51)	(0.78)
Earnings per share, diluted USD per share	(1.66)	(1.85)	(1.12)	(0.13)	(0.51)	(0.78)
Weighted average shares, basic thousands of shares	33,651	38,078	48,734	61,256	86,726	106,927
Weighted average shares, diluted thousands of shares	33,651	38,078	48,734	61,256	86,726	106,927

Fiscal years (AQST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	31,807	28,024	27,273	23,872	71,546	121,169
Inventory	2,461	4,038	5,780	6,769	6,044	6,169
Prepaid and other current assets	3,402	3,077	2,131	1,854	3,286	4,168
Total current assets	44,625	47,259	39,888	40,966	88,220	149,269
Property and equipment, net	6,873	5,055	4,085	4,179	3,799	3,893
Right-of-use asset	3,448	2,725	5,211	5,557	5,182	4,621
Total assets	62,884	61,993	57,070	57,418	101,424	160,425
Accounts payable	7,089	8,314	9,946	8,926	10,287	29,862
Accrued liabilities	8,569	8,736	7,967	6,497	5,907	5,029
Total current liabilities	21,104	21,964	39,528	18,308	18,865	47,608
Lease liability, non-current	2,846	1,946	5,085	5,399	4,968	4,337
Total liabilities	111,381	144,127	175,624	163,905	161,580	194,087
Accumulated deficit	(186,257)	(256,796)	(311,207)	(319,077)	(363,214)	(446,998)
Total stockholders' equity	(48,497)	(82,134)	(118,554)	(106,487)	(60,156)	(33,662)
Total liabilities and equity	62,884	61,993	57,070	57,418	101,424	160,425
Common shares outstanding (cover page) thousands of shares	36,214	41,468	55,871	73,301	98,871	122,045

Fiscal years (AQST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(55,783)	(70,539)	(54,410)	(7,870)	(44,137)	(83,784)
Stock-based compensation	6,581	6,819	4,381	2,689	7,099	7,624
Net cash from operating activities	(45,459)	(32,979)	(9,789)	(6,380)	(35,759)	(52,432)
Purchases of property and equipment	517	913	1,024	995	159	562
Net cash from investing activities	(517)	(913)	(2,524)	(995)	(159)	(562)
Net cash from financing activities	28,457	30,109	11,562	3,974	83,592	102,617
Net change in cash	(17,519)	(3,783)	(751)	(3,401)	47,674	49,623

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Ocugen	100,051	1,488	(12,198)*	339.1M	8.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39,267	10,131	(75,770)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.